Ipamorelin vs MK-677: A Research Comparison (2026)

Ipamorelin and MK-677 are often shelved together as "growth-hormone secretagogues," and at the receptor level they do share a target. But they are about as different as two compounds aiming at the same receptor can be: one is a compact injectable peptide, the other a non-peptide small molecule built to be swallowed. That single structural fact ripples through everything — half-life, the shape of the GH signal, how each is sourced, and how each is verified. This comparison maps those differences for laboratory research use only.

Framing up front: Both are research compounds, not approved drugs. Nothing here is dosing, supplementation, or human-use guidance, and no growth, body-composition, or performance outcomes are claimed.

Same receptor, different molecules

The shared thread is the receptor. Both compounds activate the ghrelin receptor (GHS-R1a) on the pituitary, the same door that the body's own ghrelin uses to prompt growth-hormone release. Our growth-hormone secretagogue mechanisms explainer covers that pathway in depth, and the GHRP vs GHRH piece situates it against the other secretagogue class.

Where they diverge is what they are.

Ipamorelin is a true peptide — five residues, including two unnatural amino acids that give it metabolic stability. MK-677 is not a peptide at all; it is a synthetic small molecule (a spiroindane) engineered to mimic ghrelin at GHS-R1a while surviving the gut. That is why one is injected and the other is swallowed.

Pharmacokinetics: pulse vs plateau

The most research-relevant difference is the shape of the growth-hormone signal each produces.

Ipamorelin has a short half-life and is studied for the pulsatile GH release it triggers — discrete bursts that resemble the body's natural secretory rhythm. MK-677's defining pharmacokinetic feature is the opposite: a long half-life that supports a single daily exposure and a more sustained elevation of GH-axis signaling in the models where it has been characterized.

This is also why the two are rarely framed as direct substitutes in the literature. They are better understood as different instruments for studying the same axis. Both fall under the umbrella of growth-hormone research as a goal category.

Selectivity: the cortisol-and-prolactin question

Selectivity is ipamorelin's signature. It earned its reputation by releasing growth hormone with markedly less impact on cortisol, prolactin, and appetite than the older GHRPs — GHRP-6, GHRP-2, hexarelin — that came before it. That "clean secretagogue" profile is the entire reason it became a reference research tool, and it is covered in detail in our ipamorelin research profile.

MK-677 is also GH-axis focused and is generally regarded as relatively selective among ghrelin mimetics, but its long half-life means its signaling is characterized as sustained rather than discretely selective in the way ipamorelin's pulses are. The two are not competing on the same selectivity axis: ipamorelin's claim is clean pulses, MK-677's is durable oral exposure.

Sourcing: peptide supply chain vs small-molecule supply chain

Because the two belong to different chemical classes, they live in different corners of the research-supplier market — and only one of them is in our peptide catalog.

Ipamorelin is a high-availability research peptide. As a short pentapeptide with two unnatural residues, it is comparatively tractable to synthesize, and well-made material reaches high purity readily — which means a chromatogram falling short of high purity is itself a meaningful signal. You can review its profile in the catalog at /peptides/ipamorelin, and it appears in the CJC-1295/ipamorelin blends covered in our blend buyer's guide. For sourcing specifics, see the where-to-buy index.

MK-677 is a small molecule, not a peptide, so it sits outside the peptide catalog entirely and is sourced through a different supply chain. We mention it here only for comparison; it is not a compound we deep-link in our peptide catalog, and its verification profile (small-molecule analytical methods) differs from the peptide HPLC/MS workflow.

Verification standards

For ipamorelin, the verification bar is the standard peptide one:

Our guide to reading a peptide COA explains how to separate a real batch-specific certificate from a decorative one. MK-677, as a small molecule, is verified by the analytical methods appropriate to its class rather than peptide HPLC/MS — a reminder that "secretagogue" is a functional label, not a chemical one.

Bottom line

Ipamorelin and MK-677 share a receptor and a goal — stimulating endogenous growth-hormone release — but almost nothing else. Ipamorelin is the injectable peptide prized for clean, pulsatile GH release with minimal cortisol and prolactin involvement. MK-677 is the orally-active small molecule prized for durable, once-daily exposure and a sustained signal. For a research design, the choice turns on whether you want to study episodic or sustained stimulation, and on which supply chain and verification workflow you are equipped to handle.

For the peptide side of that decision, ipamorelin's sourcing bar is straightforward: batch-specific HPLC at ≥98% and mass-spec identity confirmation. Compare it against the rest of the secretagogue class in our research library, and explore the catalog at /peptides.

For research use only. Not FDA-approved, not for human consumption. Nothing here is a growth, performance, or outcome claim for either compound.